Featured News

Does living with celiac disease impact your daily life? We need your help to advance celiac disease research and test an investigational medication.  

Is celiac disease holding you back? If so, consider joining the FB102-301 study for people who have celiac disease who are currently on a gluten-free diet. The phase 2 FB102-301 study is researching a potential new…

Is celiac disease having a significant impact on your daily life? You may be eligible for a clinical study. The ASPIRION study is a phase 2 study looking into a new, investigational study drug (amlitelimab) for patients with celiac disease.

New Phase 2 Clinical Trial: TEV-CeD2 Study

The ILLUMINATE-101 Study is a phase 2 clinical research study evaluating the safety and effectiveness of an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

What if there was a way to help your immune system become more tolerant of gluten? That’s the potential of VTP-1000, an investigational immunotherapy being studied in the AVALON celiac disease clinical trial.

On May 20 the Disease Foundation hosted its third annual award reception at Digestive Disease Week in Washington, D.C. From prestigious global research prizes to inaugural student and policy leadership awards, the event spotlighted the extraordinary contributions of individuals dedicated to improving the lives of those affected by celiac disease.

The Celiac Disease Foundation is proud to share that for the second year in a row, access to funding for celiac disease research is being made available through the U.S. DOD Congressionally Directed Medical Research Programs (DOD-CDMRP)Peer Review Medical Research Program.

The SynCeD Study is looking for adult volunteers with celiac disease to join a phase 2a clinical trial. Your participation could make a difference. 

The Celiac Disease Foundation, is proud to announce a recent grant of $200,000 from the Foster Family Foundation, which CDF will use to further its mission.